The NHS Business Services Authority (NHSBSA) has released an exploratory analysis estimating that patients could have faced prescription charges totaling approximately £837 million ($1.1 billion) in the 2023/24 period without the use of prescription prepayment certificates.
The report indicates that over three million PPCs were issued during this timeframe, with more than two-thirds being 12-month certificates - a figure that has seen consistent growth since 2018/19. Additionally, almost a million three-month certificates were distributed, marking an overall increase over the past five years.
Experimental analysis of NHS prescriptions data suggests that, without a three or 12-month PPC, patients might have incurred approximately £817 million in prescription charges. The NHSBSA plans to publish this report annually to provide ongoing insights into PPC uptake and potential patient savings.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze